

CALRETININ EXPRESSION IN THE DIFFERENTIAL DIAGNOSIS OF AMELOBLASTOMA AND KERATOCYSTIC ODONTOGENIC TUMOUR

Farzana Kalsoom*, Muhammad Atique**, Suhaib Ahmed***, Faiza Aslam****, Tariq Sarfraz*****, Shahid Jamal*****, Muhammad Tahir Khadim*****, Farhan Akhtar*****

*Armed Forces Institute of Pathology Rawalpindi, **Combined Military Hospital Lahore, ***Combined Military Hospital Rawalpindi, ****Combined Military Hospital Mangala, *****Combined Military Hospital Kharian, *****Army Medical College National University of Sciences and Technology (NUST) Islamabad, *****PNS Shifa Karachi

ABSTRACT

Objective: To determine calretinin expression by immunohistochemistry in ameloblastoma and keratocystic odontogenic tumors (KCOT) and to document the use of calretinin as a differentiating marker between the two lesions.

Study Design: A cross sectional study conducted on previously diagnosed cases of ameloblastoma and Keratocystic odontogenic tumour.

Place and Duration of Study: Armed forces Institute of Pathology, Rawalpindi Pakistan and duration was one year. (Sep 2009- Aug 2010).

Materials and Methods: Twenty cases each of Ameloblastoma and KCOT were retrieved from the record files along with their paraffin embedded blocks. Histological features of all the cases were reviewed on freshly prepared slides and a fresh diagnosis made regardless of the previous diagnosis. The immunohistochemical marker, Calretinin, was applied on both types of cases using the avidin-biotinylated peroxidase complex method. The results were interpreted.

Results: In the cases of Ameloblastoma the epithelial tumour nests showed positivity for Calretinin expression. In 85% cases; intense and diffuse staining was observed in more than 80% of the stellate reticulum like cells while 15% cases showed focal and moderate staining patterns. On the other hand KCOT showed contrary results as none of epithelial lining expressed positive staining for Calretinin, ($p < 0.001$).

Conclusion: Calretinin can be used as a useful marker for Ameloblastoma and can be used to differentiate KCOT from Ameloblastoma.

Keywords: Ameloblastoma, Calretinin, Immunohistochemical marker, Keratocystic odontogenic tumour.

INTRODUCTION

Ameloblastoma is a borderline tumour as it is locally invasive and rarely metastasizes. It has higher recurrence rate than odontogenic cysts after surgical removal¹⁻³. Keratocystic Odontogenic tumour (KCOT), previously called odontogenic keratocyst, has been renamed in the World Health Organization (WHO) 2005 histological classification of odontogenic tumours to highlight its neoplastic nature³⁻⁵. Though it has recurrence potential but it does not metastasize.

In the presence of inflammatory changes KCOT can be histologically misdiagnosed as ameloblastoma. Sometimes ameloblastoma can be misinterpreted as KCOT because of insufficient biopsy sample. So both pathologic entities can be misdiagnosed for each other⁵. Whenever the morphological patterns mimic each other, it becomes difficult for the histopathologist to make a definitive diagnosis by morphology alone and Immunohistochemistry is a very helpful diagnostic tool.

There is a need for a diagnostic aid other than light microscopy to differentiate these two entities which have entirely different biological behavior and surgical protocol. Different immunochemical markers have proven their significance while others are being investigated.

Correspondence: Dr Farzana Kalsoom, C/o Col Shahzad Mansoor, Aviation Dte GHQ Rawalpindi.

Email: shahztaha@hotmail.com

Received: 13 Dec 2012; Accepted: 10 Sep 2014

Calretinin, a 29-Kilodalton calcium binding protein belongs to large family of proteins which also includes S-100 proteins. Structurally it is characterized by 6 helix loop helix folds. These folds are binding sites of calcium⁵⁻⁶. The biological role of Calretinin is unknown while its possible role as calcium buffer and regulator of apoptosis has been proposed. Its role as most specific and sensitive marker of both benign and malignant mesotheliomas has been well established which is nearly 100%⁷⁻⁹. Expression of Calretinin is useful in central and peripheral neural tissues, convoluted tubules of kidney, Leydig and Sertoli cells of the testis, endometrium, ovarian stromal cells and adrenal cortical cells⁹⁻¹². Contrarily, a small percentage of adenocarcinomas of different origins are weakly reactive to calretinin¹³. Calretinin expression was observed in the epithelium-derived tissues during process of odontogenesis in rat molar tooth germs. It showed that preameloblast stained more intensely as compared to secretory ameloblasts¹⁴. Its role is also being investigated in diagnosing Ameloblastoma as its diagnosis becomes difficult if there is metastasis to other organs¹⁵. Studies are being conducted worldwide in order to establish the role of calretinin in diagnosing ameloblastoma and favorable results are being documented showing positive epithelial staining of calretinin in ameloblastoma. At times KCOT resembles ameloblastoma and poses a diagnostic challenge for the pathologist; therefore, use of calretinin is being studied in various parts of the world as an adjunct to differentiate the two pathologies. Thus, we selected this study to investigate the valuable potential of Calretinin in differentiating ameloblastoma and KCOT in our setup as there are no studies from this part so that we can compare the immunoreactivity of calretinin with the results of the other studies going on worldwide.

The purpose of this study was to establish whether calretinin in ameloblastoma and KCOT can serve as a marker that would be useful in the

differential diagnosis of ameloblastoma and KCOT.

MATERIALS AND METHODS

It was a descriptive, study conducted at Department of Histopathology, Armed Forces Institute of Pathology (AFIP) Rawalpindi, Pakistan from Sep 2009 to Aug 2010. Total

Table: Calretinin expression in ameloblastoma and Kcot tumer.

Nomenclature	Grading		
	Ameloblastoma (n = 20)	0(0%)	3(15%)
KCOT (n = 20)	20(100%)	0(0%)	0(0%)

$p < 0.001$




Figure: Strong calretinin staining ameloblastoma*200.

number of 40 cases was included in the study comprising of 20 previously histologically diagnosed cases of ameloblastoma and 20 previously histologically diagnosed cases of keratocystic odontogenic tumour.

Non probability convenience sampling technique was used for sampling.

Blocks with scanty and autolysed tissues or poorly processed blocks were excluded. The data on gender, age and site of involvement and radiological findings were noted from clinical files in each case.

Histological features of all the cases were reviewed on freshly prepared slides from block samples and a fresh diagnosis was made

regardless of the previous diagnosis by using the conventional microscopy.

The immunohistochemical marker, calretinin was applied on both types of cases on 4 micrometer thick sections of selected cases of ameloblastoma and keratocystic odontogenic tumour using polyclonal rabbit anticalretinin (Zymed Labs Inc. San Francisco, CA, USA) employing strepta-vidin-biotin complex immunoperoxidase technique. The slides were incubated with rabbit anti calretinin antibodies which is a purified form of rabbit anti sera and diluted in phosphate buffered saline with PH 7.4 and 1% bovine serum albumin with 0.1% sodium azide were used as preservative. Human brain tissue was used as positive control for calretinin. For negative control the primary antibody was replaced with normal serum. Immune reactivity was evaluated by assessing the percentage of positive cells along with pattern, localization in the cell and intensity of staining, using conventional light microscopy.

Age was taken as quantitative variable whereas site, sex, microscopic features of Ameloblastoma and keratocystic odontogenic tumour and pattern of immune reactivity in term of percentage and intensity were our qualitative variables.

Data had been analyzed using SPSS version 15. Descriptive statistics were used to describe results. Chi- square test was applied to compare calretinin expression between ameloblastoma and K & T cases. A p value < 0.05 was considered as significant.

RESULTS

Patients affected by Ameloblastoma were 60% males and 40% females with male to female ratio of 1.5:1. In case of KCOT, there were 55% males and 45% females with male to female ratio of 1.22:1.

The age range for ameloblastoma was between 10-77 years with mean of 31. The age range for KCOT was between 12-41 years with a mean of 25.

The most common site of tumour presentation in Ameloblastoma was mandible making upto 98% followed by maxillary ridge 2%. In KCOT the most common site of tumour presentation was also mandible.

Out of 20 cases of ameloblastoma, thirteen (65%) were of follicular and plexiform with equal frequency, two (10%) were of granular cell variant, two (10%) were arising in the dentigerous cyst, two (10%) were of acanthotic variant with squamous differentiation and one (5%) was of unicystic ameloblastoma.

The staining with Calretinin was diffuse in seventeen cases (Fig) and focal in three that was not dependent on the histological types, except for one case of unicystic ameloblastoma which showed focal pattern.

In two cases of ameloblastoma arising in dentigerous cyst the staining was positive in areas showing ameloblastic features and the epithelial lining of dentigerous cyst showed negative staining. The Calretinin expression was intense in the epithelium lining the micro or macrocysts. The intense staining of the macrocyst occur even in the absence of epithelial lining.

In all 20 cases of KCOT, the epithelial lining of the cyst showed no positive staining in all (100%) cases. Calretinin expression was significantly different in ameloblastoma and KCOT cases ($p < 0.001$).

DISCUSSION

The differential diagnosis of primary KCOT and ameloblastoma is challenging especially in small incisional biopsies as clinical, radiological and histopathological presentation could be equivocal. An attempt is made in this study to establish the role of calretinin in the differential diagnosis.

Distribution of KCOT was found higher in males in our study. Similar findings were observed in studies by Gupta et al and Pitak et al (2010)¹⁶⁻¹⁷. Mean age distribution was almost similar to the studies from California and Northern China 29.4 and 28.56 respectively.

Higher mean age was found by Gupta and poninnah¹⁶. Like other studies mandible was found to be the most frequent site of involvement by KCOT¹⁶.

Neville (2002) reported equal precipitation for both males and female in ameloblastoma³. Our study found increased frequency in males. Wide age range has also been reported by Neville similar to the patients observed in our study that ranged between 10-77 years. Like other studies mandible was found to be the most frequent site of involvement of ameloblastoma¹⁸.

Radiographically both KCOT and Ameloblastoma appear as unilocular or multilocular cysts, which is the picture in most reported cases.

Regarding calretinin expression the results of our study have demonstrated intense positive expression of Calretinin in stellate reticulum present in central core of tumour island. Whereas all the cases of KCOT showed negative expression for calretinin.

The results of our study showed similar results as that of Altini et al (2000) who showed 29 of the 31 ameloblastoma to be positive for calretinin with intense staining stellate reticulum-like cells¹⁹. De Villiers et al (2008) also observed 100% positive staining in 19 cases of ameloblastoma while 17 cases of KCOT were 100% negative for the stain. They observed the staining pattern restricted to the neoplastic epithelial counterparts⁵.

Piattelli et al (2003) investigated Calretinin expression in odontogenic cysts in U.S.A including twenty four radicular cysts, twenty four follicular cysts and twenty two Odontogenic keratocystic tumours. All the radicular cysts, follicular cysts and all Odontogenic keratocystic tumours showed negative expression for calretinin both in epithelial and stromal components¹⁸.

Coleman et al (2001) observed lining epithelium of eight cases of unicystic ameloblastoma, six cases of dentigerous cyst, six

cases of KCOT, and four cases of solid/multicystic ameloblastoma for the expression of calretinin. No positive staining was observed in any of the dentigerous cysts and keratocystic odontogenic tumor linings. In comparison, coarse dark brown staining was seen in the stellate reticulum of solid multicystic ameloblastoma and more superficial epithelial layers of unicystic ameloblastoma. Thus they established calretinin as a specific immunohistochemical marker for neoplastic ameloblastic tissue that can be used as an important diagnostic aid in the differential diagnosis of unicystic ameloblastoma and cystic odontogenic lesions²⁰.

In Iran Alaeddini et al (2008) studied comparative expression of Calretinin in selected odontogenic tumours. Total 55 odontogenic tumours were assessed for calretinin expression. They include 20 cases of Ameloblastoma, 5 calcifying epithelial odontogenic tumour, 10 adenomatoid odontogenic tumours, 10 ameloblastic fibromas and 10 cases of odontogenic myxomas. All cases of ameloblastomas showed positive staining for calretinin while remaining tumours were negative for the stain. The difference in proportion for the calretinin expression in the two groups was significant²¹.

CONCLUSION

The ameloblastomas, in contrast to KCOT were consistently reactive for Calretinin, therefore, it may be an important and useful diagnostic aid to differentiate ameloblastoma from KCOT.

Conflict of Interest

This study has no conflict of interest to declare by any author.

REFERENCES

1. Rosai J. Mandible and maxilla. Inc: Micheal Huston. Rosai and Ackerman's Surgical Pathology, Missouri, Elsevier 2004; 279-296.
2. Small IA, Waldron CA. Ameloblastomas of the jaws. Oral Surg Oral Med Oral Pathol 1995; 8: 281-297.
3. Neville BW, Damm D, Allen CM, Bouquot JE. Oral Maxillofacial Pathology, USA, W.B Saunders Company; 2002.
4. Barnes L, Eveson JW, Reichart P, Sidransky D, Editors. Classification of Tumors of the Head and Neck. Lyon: WHO/IACR 2005; 306-7.

5. Devilliers P, Liu H, Suggs C, Simmons D, Daly B, Zhang S, et al. Calretinin Expression in the Differential Diagnosis of Human Ameloblastoma and Keratocystic Odontogenic Tumor. *Am Surg Pathol* 2008; 32: 256-9.
 6. Rogers J, Khan M, Ellis J. Calretinin and others CaBPs in the nervous system. *Adv Exp Med Biol* 1990; 195-203.
 7. Dei Tos AP, Doglioni C. Calretinin a novel tool for diagnostic immunohistochemistry. *Adv Anat Pathol* 1998; 5: 61-6.
 8. Gandler JC, Gotzos V, Fellay B, Schwaller B. Inhibition of the proliferative cycle and apoptotic events in WiDr cells after down regulation of the calcium-binding protein calretinin using antisense oligodeoxynucleotides. *Exp Cell Res* 1996; 225: 399-410.
 9. Doglioni C, Die Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR, et al. Calretinin a novel immunocytochemical marker for mesothelioma. *Am J Surg Pathol* 1996; 20: 1037-1046.
 10. Saydan N, Salicio V, Cappelli Gtzos B, Gotzos V. Expression of calretinin in human cell lines and cell cycle analysis by flow cytometry. *Anticancer Research* 2001; 21: 181-8.
 11. Rogers JH. calretinin: gene for a Novel calcium-binding protein expressed principally in neurons. *J cell Biol* 1987; 105: 1343-1353.
 12. Lugli A, Forster Y, Haas P, Noctico A, Bucher C, Bissiq H, et al. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. *Hum Pathol* 2003; 34: 994-1000.
 13. Ordonez NG. Value of calretinin immunostaining in differentiating mesothelioma from lung adenocarcinoma. *Mod Pathol* 1998; 11: 929-33.
 14. Mistry D, Altini M, Coleman HG, Ali H, Mariorano E. The spatial and temporal expression of calretinin in developing rat molars (*Ratus norvegicus*). *Arch Oral Biol* 2001; 46: 973-81.
 15. Muhammad A, Akhtar Q. Ameloblastoma of mandible. *Pakistan Armed Forces Medical journal*. 2006; 2: 34-7.
 16. Gupta B, Ponniah I. The pattern of odontogenic tumors in a government teaching hospital in the southern Indian state of Tamil Nadu. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2010; 110: 32-9.
 17. Pitak Arnnop A, Chaine A, Oprean N, Dhanuthia K, Bertrand JC, Bertolus C. Management of odontogenic keratocysts of the jaw: A ten-year experience with 120 consecutive lesions. *J Cranio-Maxillofacial Surgery* 2010; 38: 358-64.
 18. Piattelli A, Fioroni M, Lezzi G, Rubini C. Calretinin Expression in Odontogenic Cysts *J Endod* 2003; 29: 394-6.
 19. Altini M, Coleman HG, Doglioni C, Favia G, Mariorano E. Calretinin expression in ameloblastomas. *Histopathology* 2000; 37: 27-32.
 20. Coleman H, Altini M, Ali H, Doglioni C, Favia G, Miorano E. Use of calretinin in the differential diagnosis of unicystic ameloblastomas. *Histopathology*. 2001; 38: 312-7.
 21. Alaeddini M, Moghadam S, Baghaii F. Comparative expression of calretinin in selected odontogenic tumours: a possible relationship to histogenesis *Histopathology* 2008; 52: 299-304.
-